United Therapeutics (UTHR) Tops Q1 EPS by 55c, Revenues Beat
Get Alerts UTHR Hot Sheet
Revenue Growth %: +22.7%
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $3.49, $0.55 better than the analyst estimate of $2.94. Revenue for the quarter came in at $379.1 million versus the consensus estimate of $368.95 million.
"2021 is already a historic year for United Therapeutics, with the recent FDA approval and launch of Tyvaso for treatment of PH-ILD, submission of the Tyvaso DPI NDA, and the launch of our Remunity® Pump for Remodulin®," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "In addition to these product launches and the potential Tyvaso DPI approval in December, we are progressing our late-stage pipeline with the commencement of the pivotal TETON study of Tyvaso in IPF, continued enrollment of the pivotal PERFECT study of Tyvaso in PH-COPD, and the ongoing pivotal ADVANCE studies of ralinepag."
"Following approval in late March, we're already gaining traction with physicians for Tyvaso in PH-ILD, with patient referrals and starts beginning in April," said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. "The commercial launch of Tyvaso in PH-ILD builds on the momentum we're already seeing for the Remunity Pump for Remodulin, which provides significant improvements over legacy subcutaneous delivery options."
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- urban-gro Inc. (UGRO) Misses Q4 EPS by 22c, offers outlook
- VNET Group (VNET) Tops Q4 EPS by 18c, provides guidance
- McCormick (MKC) shares pop on Q1 top and bottom line beat
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!